A class of diabetes medications called SGLT2 inhibitors is now proven to slow kidney disease progression in people who don’t have diabetes at all. Dapagliflozin (brand name Farxiga) and empagliflozin (brand name Jardiance), both originally developed to lower blood sugar, have earned FDA approval for treating chronic kidney disease regardless of whether a patient has diabetes. In the landmark DAPA-CKD trial, dapagliflozin reduced the risk of declining kidney function, end-stage kidney disease, or kidney and cardiovascular death by 39 percent compared to placebo, and one-third of the participants in that trial were non-diabetic patients who saw the same protective benefits. For families navigating dementia care, where kidney health and medication management already demand close attention, this is a development worth understanding.
The implications stretch beyond nephrology clinics. Chronic kidney disease affects roughly 37 million Americans, many of whom have no diabetes diagnosis, and kidney decline is closely linked to cognitive deterioration and vascular dementia risk. A drug that can halve the rate of kidney function loss, as empagliflozin did in the EMPA-KIDNEY trial, has downstream consequences for brain health that researchers are only beginning to map. This article covers how these drugs work independently of blood sugar, what the major clinical trials found in non-diabetic populations, who qualifies for treatment under current FDA approvals, and what limitations and risks patients should weigh before starting therapy.
Table of Contents
- How Are Diabetes Drugs Reducing Kidney Disease Progression in Non-Diabetics?
- What the DAPA-CKD and EMPA-KIDNEY Trials Found
- Benefits That Persist After Stopping the Drug
- Who Qualifies and What Current FDA Approvals Cover
- Risks, Side Effects, and When These Drugs May Not Be Appropriate
- The Connection Between Kidney Health and Cognitive Decline
- Where the Research Goes From Here
- Conclusion
- Frequently Asked Questions
How Are Diabetes Drugs Reducing Kidney Disease Progression in Non-Diabetics?
The kidney-protective effects of SGLT2 inhibitors operate through mechanisms that have nothing to do with blood sugar control. These drugs work by promoting natriuresis and osmotic diuresis, which reduces intraglomerular pressure, the hydraulic force inside the kidney’s filtering units. Over time, excessive intraglomerular pressure damages the delicate capillary walls of the glomeruli, leading to scarring and progressive loss of function. By easing that pressure, SGLT2 inhibitors slow the structural damage regardless of whether elevated glucose is part of the picture. Researchers believe the GFR reduction seen early in treatment reflects postglomerular vasodilation rather than preglomerular vasoconstriction, a distinction that matters because it means the drug is relieving strain on the kidney’s outflow side rather than simply choking off blood supply. this mechanism helps explain why the benefits show up so consistently in non-diabetic populations.
A February 2026 meta-analysis found that SGLT2 inhibitors reduced progressive kidney disease risk in non-diabetic patients with an odds ratio of 0.69, meaning roughly a 31 percent lower likelihood of disease progression compared to placebo. Overall, across diabetic and non-diabetic populations combined, these drugs reduce chronic kidney disease progression risk by approximately 38 percent and slow the annual decline in estimated glomerular filtration rate by about 51 percent versus placebo. To put that in concrete terms, for a 72-year-old woman with stage 3 CKD and no diabetes, starting one of these medications could mean the difference between needing dialysis in five years and maintaining stable kidney function for a decade or longer. One comparison worth noting is how these drugs stack up against older interventions. ACE inhibitors and ARBs, the previous standard of care for slowing CKD, typically reduce progression risk by 15 to 25 percent. SGLT2 inhibitors are now used alongside those medications, not as replacements, creating a layered defense that offers substantially more protection than either drug class alone.
What the DAPA-CKD and EMPA-KIDNEY Trials Found
The DAPA-CKD trial, published in the new England Journal of Medicine, enrolled 4,304 patients with chronic kidney disease. The 39 percent reduction in the composite endpoint of kidney function decline, end-stage kidney disease, or death from kidney or cardiovascular causes was striking enough that the trial was stopped early for overwhelming efficacy. Among the one-third of participants who did not have diabetes, the benefits were statistically consistent with those seen in diabetic patients. Critically, no non-diabetic patient in the trial developed severe hypoglycemia or diabetic ketoacidosis, two concerns that might have given clinicians pause about prescribing a diabetes drug to someone without the disease. The EMPA-KIDNEY trial reinforced these findings with empagliflozin in an even broader population.
Primary outcome events, defined as kidney disease progression or cardiovascular death, occurred in 13.1 percent of the empagliflozin group versus 16.9 percent of the placebo group over a median follow-up of two years, a 29 percent relative risk reduction. More than half the participants, 3,569 patients representing 54 percent of the trial, did not have diabetes, and the benefits held in that group. Perhaps the most compelling finding was that empagliflozin halved the rate of kidney function decline: the chronic eGFR slope went from negative 2.75 to negative 1.37 milliliters per minute per 1.73 square meters per year. However, these trials enrolled patients who were already on optimized background therapy, including ACE inhibitors or ARBs in most cases. Patients who cannot tolerate renin-angiotensin system blockade, or who have other contraindications, may not see the same magnitude of benefit. The trials also excluded patients on dialysis and those with polycystic kidney disease, so extending these results to every form of CKD requires caution.
Benefits That Persist After Stopping the Drug
One of the more remarkable findings came from long-term follow-up data published in February 2025. Researchers tracking EMPA-KIDNEY participants found that the cardiorenal benefits of empagliflozin continued for up to 12 months after the drug was discontinued. This is unusual in medicine, where most drug effects fade within days or weeks of stopping treatment. The sustained benefit suggests that SGLT2 inhibitors may be doing more than temporarily easing kidney workload. They may be allowing structural recovery or reducing inflammatory and fibrotic processes that would otherwise compound over time.
For dementia caregivers managing complex medication regimens, this finding has practical significance. If a patient needs to temporarily stop an SGLT2 inhibitor for surgery, an acute illness, or a period of dehydration risk, the kidney protection does not vanish overnight. That buffer provides some reassurance during the inevitable disruptions that come with managing health in older adults, particularly those with cognitive decline who may have difficulty maintaining consistent medication adherence. A newer randomized trial focused specifically on non-diabetic patients with stage 4 CKD, the most advanced stage before dialysis, found that dapagliflozin significantly decreased GFR by 1.88 milliliters per minute per 1.73 square meters and reduced proteinuria by 0.50 grams per 24 hours compared to placebo at six weeks. These results matter because stage 4 patients were historically considered too far along to benefit from new interventions, and many clinicians were reluctant to start SGLT2 inhibitors at such low kidney function levels.
Who Qualifies and What Current FDA Approvals Cover
Dapagliflozin received FDA approval in 2021 for chronic kidney disease at risk of progression regardless of diabetes status, making it the first SGLT2 inhibitor approved for this indication. Empagliflozin followed in 2023 with the same broad approval. Both drugs are approved for use in patients with eGFR as low as 20 milliliters per minute per 1.73 square meters, which corresponds to stage 4 CKD. The 2026 ADA Standards of Care in Diabetes now includes SGLT2 inhibitors as a cornerstone of CKD management in its chapter on chronic kidney disease and risk management. The choice between dapagliflozin and empagliflozin involves some practical tradeoffs. Both have demonstrated kidney protection in large trials, and head-to-head comparisons are limited.
Dapagliflozin has slightly longer post-marketing experience in the CKD indication given its two-year head start on FDA approval. Empagliflozin has the longer-term follow-up data showing sustained benefits after discontinuation. Formulary coverage and copay structures often drive the decision in practice, and patients should check whether their insurance plan favors one over the other. Both are taken once daily as oral tablets, which is a meaningful advantage for older patients already juggling multiple medications. One limitation to keep in mind is that benefits have been observed even in patients with minimal or no albuminuria, the protein leakage in urine traditionally used to gauge kidney damage severity. This is good news for patients who might not have been considered candidates under older treatment paradigms, but it also means clinicians need to think about who to screen and when to start therapy in people who may have no obvious symptoms of kidney trouble.
Risks, Side Effects, and When These Drugs May Not Be Appropriate
SGLT2 inhibitors are not free of side effects. The most common issues include genital yeast infections, urinary tract infections, and increased urination, all consequences of the drug’s mechanism of pushing more glucose and fluid through the kidneys. For older adults, particularly those with dementia who may already struggle with hydration and incontinence, the increased urination can be a meaningful quality-of-life concern. Dehydration risk is real, especially in hot weather or during illnesses that cause vomiting or diarrhea, and caregivers need to be vigilant about fluid intake. While the DAPA-CKD trial showed no cases of severe hypoglycemia or ketoacidosis among non-diabetic participants, these risks are not zero in real-world practice, particularly if a patient has undiagnosed prediabetes or is taking other medications that affect blood sugar. Euglycemic diabetic ketoacidosis, a rare but serious condition where ketoacidosis develops without significantly elevated blood sugar, has been reported with SGLT2 inhibitors and can be difficult to recognize because the usual warning sign of very high glucose is absent.
Patients scheduled for surgery are typically advised to stop these medications several days beforehand to reduce this risk. The meta-analysis data, showing an odds ratio of 0.69 for kidney disease progression in non-diabetics, is encouraging but not a guarantee. Some patients will progress despite treatment, and SGLT2 inhibitors do not reverse existing kidney damage. They slow further decline. For patients already on dialysis or with polycystic kidney disease, the evidence does not support starting these medications. And for anyone with a history of recurrent urinary tract infections or severe genital fungal infections, the risk-benefit calculus may tilt differently.
The Connection Between Kidney Health and Cognitive Decline
For readers focused on dementia and brain health, the kidney-brain axis deserves attention. Chronic kidney disease is an independent risk factor for cognitive decline and vascular dementia. The mechanisms overlap: hypertension, endothelial dysfunction, chronic inflammation, and small vessel disease damage both organs simultaneously. A patient whose kidney function is declining at 2.75 milliliters per minute per year instead of 1.37 is also a patient whose cerebrovascular health is likely deteriorating faster.
By preserving kidney function, SGLT2 inhibitors may indirectly protect cognitive function, though direct evidence from dementia-focused trials is still emerging. Consider an older adult with moderate CKD and early signs of cognitive impairment. Every hospitalization for acute kidney injury, every bout of uremia-related confusion, every medication adjustment forced by declining kidney function creates a setback in cognitive stability. Slowing kidney disease progression by 38 to 51 percent means fewer of those destabilizing events over the years that matter most.
Where the Research Goes From Here
The pace of evidence accumulation around SGLT2 inhibitors in non-diabetic kidney disease has been remarkably fast. From the first FDA approval in 2021 to comprehensive meta-analyses in 2026, the drug class has moved from a surprising secondary finding to a first-line treatment recommendation in under five years. Ongoing research is examining whether these drugs offer similar protection in pediatric kidney disease, IgA nephropathy, and other specific causes of CKD that were underrepresented in the major trials.
The question that matters most for brain health audiences is whether the kidney protection translates into measurable cognitive preservation. Several observational studies are underway, and the sustained post-discontinuation benefit seen in the EMPA-KIDNEY follow-up raises the intriguing possibility that SGLT2 inhibitors trigger durable biological changes rather than merely masking symptoms. If that holds up, we may be looking at a drug class that protects two of the organs most vulnerable to aging, the kidneys and the brain, through a single daily pill.
Conclusion
SGLT2 inhibitors have fundamentally changed the treatment landscape for chronic kidney disease, and the most significant development is that their benefits extend fully to patients without diabetes. Dapagliflozin and empagliflozin both carry FDA approval for CKD regardless of diabetes status, with clinical trials showing risk reductions of 29 to 39 percent for major kidney outcomes and a halving of the rate of kidney function decline. The evidence now extends to patients with stage 4 CKD and those with minimal proteinuria, populations once considered beyond the reach of these therapies.
For anyone managing or caring for a person with both kidney disease and cognitive concerns, the conversation with a nephrologist about SGLT2 inhibitors should happen sooner rather than later. The drugs are not without side effects, and they require attention to hydration and infection risk, particularly in older adults. But the magnitude of kidney protection, the durability of benefits even after discontinuation, and the potential downstream effects on brain health make this one of the most consequential pharmacological developments in years. Talk to your doctor, bring the trial names DAPA-CKD and EMPA-KIDNEY to the appointment, and ask whether these medications belong in the treatment plan.
Frequently Asked Questions
Can someone without diabetes really take a diabetes drug for kidney disease?
Yes. Both dapagliflozin (Farxiga) and empagliflozin (Jardiance) have FDA approval specifically for chronic kidney disease regardless of diabetes status. The kidney-protective mechanism is independent of blood sugar lowering.
What were the main risks for non-diabetic patients in clinical trials?
In the DAPA-CKD trial, no non-diabetic patients developed severe hypoglycemia or diabetic ketoacidosis. The most common side effects are genital yeast infections, urinary tract infections, and increased urination. Dehydration is a concern that requires monitoring.
How low can kidney function be before starting these drugs?
Both dapagliflozin and empagliflozin are FDA-approved for use down to an eGFR of 20 mL/min/1.73 m², which corresponds to stage 4 CKD. A newer trial has also shown benefits in non-diabetic stage 4 patients specifically.
Do the kidney benefits stop when you stop the medication?
Not immediately. Long-term follow-up from the EMPA-KIDNEY trial, published in February 2025, found that cardiorenal benefits continued for up to 12 months after empagliflozin was discontinued.
How do SGLT2 inhibitors compare to older kidney-protective drugs like ACE inhibitors?
They are used in addition to ACE inhibitors or ARBs, not as replacements. SGLT2 inhibitors reduce CKD progression risk by approximately 38 percent, while ACE inhibitors and ARBs typically offer 15 to 25 percent risk reduction. Combined, they provide stronger protection.
Does protecting the kidneys also protect the brain?
Chronic kidney disease is an independent risk factor for cognitive decline and vascular dementia. By slowing kidney function loss, SGLT2 inhibitors may reduce the cerebrovascular damage, hospitalizations, and metabolic disruptions that accelerate cognitive deterioration, though direct trial evidence for cognitive outcomes is still being gathered.
